<DOC>
	<DOCNO>NCT03026803</DOCNO>
	<brief_summary>This phase II trial study well give oxaliplatin capecitabine together work treat patient liver cancer .</brief_summary>
	<brief_title>A Study Oxaliplatin Capecitabine Unresectable Metastatic Hepatocellular Cancer</brief_title>
	<detailed_description>Drugs use chemotherapy , oxaliplatin capecitabine , work different way stop growth tumor cell , either kill cell stop divide . Giving drug together may kill tumor cell .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Patients must histologically confirm hepatocellular carcinoma recurrent , metastatic unresectable . Patients may two prior chemotherapy regime . In addition , may previous radiation , chemoembolization , and/or alcohol injection . Patients must measurable disease , define lesion accurately measure least one dimension ( long diameter record ) ≥20 mm conventional technique ≥10 mm spiral CT scan , clearly progress observation interval prior participation study . Pleural effusion ascites consider measurable , may present addition measurable lesion ( ) . Karnofsky performance status &gt; 70 % . Patients expect survival least 2 month . Leukocytes &gt; 3,000/µl Absolute neutrophil count &gt; 1,500/µl Platelets &gt; 50,000/µl Total bilirubin &lt; 3.0 g/dl AST ( aspartate aminotransferase ) ( serum glutamic oxaloacetic transaminase ( SGOT ) /ALT ( alanine aminotransferase ) ( serum glutamic pyruvic transaminase ) ( SGPT ) &lt; 5 time institutional upper limit normal Creatinine &lt; 2.0 OR measure calculated creatinine clearance &gt; 60 mL/min patient creatinine level institutional normal Brain metastasis exclusion , however , patient eligible successful control brain tumor ( ) surgery stereotactic RT . Patients evidence clinically significant neuropathy . All prior therapy must complete least 4 week prior patient 's entry trial . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Breastfeeding discontinue mother treated oxaliplatin . Subjects chronic hepatitis B C may undergo treatment α interferon and/or ribavirin , long meet criterion entry study . Ability understand willingness sign write informed consent document . Patients prior oxaliplatin xeloda treatment undergo therapy investigational agent . History allergy platinum compound antiemetic appropriate administration conjunction protocoldirected chemotherapy . Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia . HIVpositive patient receive antiretroviral therapy ( HAART ) exclude study possible pharmacokinetic interaction . Patients diagnosis pulmonary fibrosis pulmonary interstitial process . Patients unable swallow capecitabine exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>